Skip to main content
RGEN
NASDAQ Life Sciences

Repligen Reports Strong Q2 Results, Raises Full-Year Revenue & Adjusted EPS Guidance

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Instrument Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$133.67
Mkt Cap
$7.396B
52W Low
$100.99
52W High
$175.77
52W Position info
32% above low
Off High info
24% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

RGEN sits 32% above its 52-week low of $100.99.

Summary

Repligen announced strong Q2 2026 financial results with 13% organic revenue growth and a 55% increase in adjusted operating income, leading to an upward revision of its full-year guidance.


Key Events · Earnings and Guidance · RGEN

  • Q2 Revenue Growth

    Reported $204 million in Q2 revenue, a 12% year-over-year increase (13% organic).

  • Adjusted Profitability Surges

    Adjusted operating income increased 55% to $34 million, and adjusted EPS rose to $0.54 from $0.37 year-over-year.

  • Full-Year Guidance Raised

    Increased full-year 2026 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS to $2.03-$2.09.

  • Strong Cash Position

    Ended Q2 with $810 million in cash, cash equivalents, and marketable securities.


Analysis · RGEN · Life Sciences

Repligen delivered robust second-quarter financial results, exceeding expectations with strong organic revenue growth and a significant increase in adjusted operating income and EPS. The company also raised its full-year 2026 guidance for both organic revenue growth and adjusted earnings per share, indicating increased confidence in its business outlook. This positive performance comes shortly after the announcement of a major acquisition, suggesting the company is executing well on both organic growth and strategic expansion.

How filings like this one have moved

In the 30 days to Sep 12, 2026, 35.8% of the 1618 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RGEN was trading at $133.67 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.4B. The 52-week trading range was $100.99 to $175.77. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RGEN - Latest Insights

RGEN
Sep 08, 2026, 5:26 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $168.53
Real-time Price: $165.20 info
Change: -$3.33 (-2%) info
Market Cap: $9.322B info
RGEN
Sep 04, 2026, 5:19 PM EDT
Filing Type: 424B3
Importance Score:
7
Price at Filing: $167.60
Real-time Price: $165.20 info
Change: -$2.40 (-1%) info
Market Cap: $9.322B info
RGEN
Sep 03, 2026, 7:56 PM EDT
Filing Type: S-4/A
Importance Score:
8
Price at Filing: $173.81
Real-time Price: $165.20 info
Change: -$8.61 (-5%) info
Market Cap: $9.322B info
RGEN
Aug 24, 2026, 9:50 PM EDT
Filing Type: S-4
Importance Score:
9
Price at Filing: $180.60
Real-time Price: $165.20 info
Change: -$15.40 (-9%) info
Market Cap: $9.322B info
RGEN
Jul 29, 2026, 4:19 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $141.23
Real-time Price: $165.20 info
Change: +$23.97 (+17%) info
Market Cap: $9.322B info